Multiple Myeloma Market - Infographics - AMR

The multiple myeloma market size is projected to reach $53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.

PORTLAND, OREGON, UNITED STATES, February 7, 2024 /EINPresswire.com/ -- According to the report published by Allied Market Research, the global multiple myeloma market garnered $19.66 billion in 2021 and is estimated to generate $53.52 billion by 2031, manifesting a CAGR of 10.5% from 2022 to 2031. The report provides an extensive analysis of changing market dynamics, major segments, value chains, competitive scenarios, and regional landscapes. This research offers valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒚 𝒐𝒇 𝑹𝒆𝒑𝒐𝒓𝒕- https://www.alliedmarketresearch.com/request-sample/3725

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-19 𝐨𝐧 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐌𝐲𝐞𝐥𝐨𝐦𝐚 𝐌𝐚𝐫𝐤𝐞𝐭:

The COVID-19 outbreak exerted a detrimental impact on the global multiple myeloma market, as social distancing measures halted numerous clinical trials. Concurrently, shortages of medical professionals, funding constraints, and lockdowns exacerbated the challenge of patients accessing timely treatments.

Supply chain disruptions stemming from the pandemic further limited the availability of medications for multiple myeloma. Additionally, research and development efforts suffered significant setbacks, delaying the progress of new therapies and treatments. Nonetheless, the global multiple myeloma market has shown signs of recovery in the post-pandemic era.

In terms of drug type, the protease inhibitors segment accounted for over a third of the global multiple myeloma market revenue and is projected to maintain its dominance by 2031, with the fastest Compound Annual Growth Rate (CAGR) of 11.1% throughout the forecast period. The report also examines segments such as chemotherapy, monoclonal antibody, and others.

Regarding end users, hospitals represented the largest share in 2021, contributing to nearly two-thirds of the global multiple myeloma market revenue and are expected to sustain their lead during the forecast period, with the fastest CAGR of 10.7%. Clinics and other segments were also evaluated in the study.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (411 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬)
https://www.alliedmarketresearch.com/checkout-final/multiple-myeloma-market

In terms of disease type, the active multiple myeloma segment held the largest share in 2021, comprising over four-fifths of the global multiple myeloma market and is anticipated to maintain its dominance in revenue during the forecast period, with the fastest CAGR of 10.6%. The report also discusses the smoldering multiple myeloma segment.

Regionally, North America dominated the market in 2021, capturing over a third of the global multiple myeloma market revenue and is expected to maintain its dominance by 2031. Conversely, the Asia-Pacific region is projected to exhibit the fastest CAGR of 11.2% throughout the forecast period. The report also covers Europe and LAMEA provinces.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the multiple myeloma market analysis from 2021 to 2031 to identify the prevailing multiple myeloma market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the multiple myeloma market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global multiple myeloma market trends, key players, market segments, application areas, and market growth strategies.

𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐭𝐮𝐝𝐲

• By drug type, the protease inhibitor segment dominated the market in 2021.

• On the basis of disease type, the active multiple myeloma segment led the market in 2021.

• Depending on end user, hospitals was the prominent segment in 2021.

• Region wise, North America exhibited the highest growth in 2021, and is expected to grow during the forecast period.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/3725

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
Teva Pharmaceutical Industries
Pfizer Inc.
Takeda Pharmaceutical Company Ltd
Baxter International Inc.
Johnson and Johnson
Novartis AG
Amgen Inc.
Bristol-Myers Squibb Company
Abbvie Inc
Sanofi

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲-
𝐁𝐨𝐭𝐮𝐥𝐢𝐧𝐮𝐦 𝐓𝐨𝐱𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/botulinum-toxin-market-A11935
𝐯𝐢𝐫𝐚𝐥 𝐯𝐞𝐜𝐭𝐨𝐫 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/viral-vector-production-market-A13615

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn